Fintech

Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed

Prnewswire·March 25, 2026 at 12:09 PM

/PRNewswire/ -- Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

EU Auditor Seeks Reforms for Cross-Border Services
PYMNTS
Stablecoin Regulations Focus on Wallets for Adoption
PYMNTS
Crypto market structure bill faces fractured industry reaction
CoinDesk
Platforms Restrict AI Agent Access
PYMNTS

Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed

EU Auditor Seeks Reforms for Cross-Border Services

Stablecoin Regulations Focus on Wallets for Adoption

Crypto market structure bill faces fractured industry reaction

Platforms Restrict AI Agent Access